<DOC>
	<DOCNO>NCT00672386</DOCNO>
	<brief_summary>The purpose study investigate effectiveness safety 12 week treatment R256918 patient Type 2 Diabetes Mellitus take metformin . The primary measure effectiveness change concentration glycated hemoglobin ( HbA1c ) treatment . Glycated hemoglobin substance red blood cell form blood sugar ( glucose ) attach hemoglobin measure diabetic status . Additional measure include fast glucose , lipid level , body weight . Safety assessment perform trial include laboratory test , vital sign measurement , adverse event reporting .</brief_summary>
	<brief_title>A Study Safety Effectiveness R256918 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This randomize ( assign study drug chance ) , double-blind ( patient investigator know whether patient assign receive study drug placebo ) , placebo-controlled study involve patient Type 2 Diabetes Mellitus take metformin . Patients randomize one 4 treatment group receive study drug ( R256918 : 5 mg , 10 mg , 15 mg twice daily ) placebo period 12 week . The study consist screen period , baseline visit , treatment period 12 week , follow-up visit . During treatment period , patient visit center every two week . On visit , patient come clinic 8 hour fast . Effectiveness assessment blood sample include level fast hemoglobin type A1c ( HbA1c ) , glucose , cholesterol , triglyceride , insulin , C-peptide , gastrointestinal hormone . Patients monitor fast blood glucose record diary . Insulin sensitivity beta cell ( insulin-producing cell pancreas ) function evaluate . Waist hip circumference measure . Safety evaluation , include incidence adverse event , clinical laboratory result , vital sign , electrocardiogram , perform study . Patients complete questionnaire related treatment satisfaction study medication . Patients receive dietary counseling instruct remain calorically appropriate diet maximum 30 percent ( % ) calories derive fat ( accordance local practice guideline treatment type 2 diabetes mellitus ) , entire study . Patients continue take metformin dose accord dose regimen study . The overall duration study patient approximately 18 week . The study evaluate effect R25691 glucose-dependent insulin secretion , weight loss change insulin sensitivity tolerability type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>History Type 2 Diabetes Mellitus treat stable dose metformin least 2 month Women must postmenopausal surgically incapable childbearing sexually active , practice effective method birth control BMI 25 45 kg/m2 HbA1c 7 % 10 % , inclusive Fasting plasma glucose exceed 240mg/dL ( 13.3mmol/L ) Diabetes type 2 diabetes mellitus Treatment oral antidiabetic agent ( metformin ) insulin 12 week baseline visit History intolerance hypersensitivity sulfonylurea sitagliptin History clinically significant gastrointestinal , hepatic cardiovascular disease Active proliferative diabetic retinopathy History diabetic gastroparesis concurrent use systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Adult-Onset Diabetes Mellitus</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Body Weight</keyword>
	<keyword>Metformin</keyword>
</DOC>